Have any questions? 706-721-6582 or cts@augusta.edu
- GCT1015-05/GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Clinical Trial
GCT1015-05/GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
The purpose of this study is to further investigate the safety and tolerability profile of tisotumab vedotin in combination with either pembrolizumab, carboplatin, or bevacizumab in subjects with cervical cancer. The results of this trial will help to determine the maximum tolerated dose and recomended dose of the study drugs.
Eligibility Criteria
- Subjects must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after standard of care streatments or are ineligible or intolerant to standard of care for recurrent or stage IVB cervical cancer. Must not have received prior systemic therapy for recurrent or stage IVB cervical cancer. Must be at least 18 years of age or older on the day of signing consent.
RESEARCH. INNOVATION. DISCOVERY.